Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Batoclimab for Thyroid Eye Disease
NCT05517447Phase 3Terminated
- Sponsor
- Immunovant, Inc.
- Start
- Nov 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of batoclimab in thyroid eye disease (TED), sponsored by Immunovant, Inc.. Started Nov 2022; status: terminated.
02
Drugs
batoclimab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05517447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517447.